|
1
|
World Health Organization (WHO), . Global
Tuberculosis report. WHO; Geneva: 2023, http://www.who.int/tb/publications/global_report/en/November
7–2023
|
|
2
|
Shimony S, Stahl M and Stone RM: Acute
myeloid leukemia: 2023 update on diagnosis, risk-stratification,
and management. Am J Hematol. 98:502–526. 2023. View Article : Google Scholar
|
|
3
|
Döhner H, Wei AH, Appelbaum FR, Craddock
C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian
RP, et al: Diagnosis and management of AML in adults: 2022
recommendations from an international expert panel on behalf of the
ELN. Blood. 140:1345–1377. 2022. View Article : Google Scholar
|
|
4
|
Sekeres MA, Guyatt G, Abel G, Alibhai S,
Altman JK, Buckstein R, Choe H, Desai P, Erba H, Hourigan CS, et
al: American Society of Hematology 2020 guidelines for treating
newly diagnosed acute myeloid leukemia in older adults. Blood Adv.
4:3528–3549. 2020. View Article : Google Scholar
|
|
5
|
Kantarjian H: Acute myeloid leukemia-major
progress over four decades and glimpses into the future. Am J
Hematol. 91:131–145. 2016. View Article : Google Scholar
|
|
6
|
Malone JL, Ijaz K, Lambert L, Rosencrans
L, Phillips L, Tomlinson V, Arbise M, Moolenaar RL, Dworkin MS and
Simoes EJ: Investigation of healthcare-associated transmission of
Mycobacterium tuberculosis among patients with malignancies at
three hospitals and at a residential facility. Cancer.
101:2713–2721. 2004. View Article : Google Scholar
|
|
7
|
Jain A, Prakash G, Singh C, Lad D, Khadwal
A, Suri V, Malhotra P, Kumari S, Varma N and Varma S: Analysis of
clinical profile and outcome of tuberculosis in patients with acute
leukemia. Indian J Hematol Blood Transfus. 34:430–442. 2018.
View Article : Google Scholar
|
|
8
|
Leukemia & Lymphoma Group, Chinese
Society of Hematology and Chinese Medical Association, . Chinese
guidelines for diagnosis and treatment of adult acute myeloid
leukemia (not APL) (2023). Zhonghua Xue Ye Xue Za Zhi. 44:705–712.
2023.(In Chinese).
|
|
9
|
Ji L, Yang W, Xu XF and Xu YQ: A case
report of complete remission of acute myeloid leukemia combined
with DNMT3A, FLT3-TKD, and IDH2 gene mutations and active pulmonary
tuberculosis treated with homeharringtonine + venetoclax +
azacytidine. Front Med (Lausanne). 10:11807572023. View Article : Google Scholar
|
|
10
|
Hematology Oncology Committee of China
Anti-Cancer Association; Chinese Society of Hematology Chinese
Medical Association; Chinese Society of Pathology Chinese Medical
Association, . Expert consensus on the application of
next-generation sequencing in hematological neoplasms (2018).
Zhonghua Xue Ye Xue Za Zhi. 39:881–886. 2018.(In Chinese).
|
|
11
|
Sun Y, Yao X, Ni Y, Peng Y and Shi G:
Diagnostic Efficacy of T-SPOT.TB for active tuberculosis in adult:
A retrospective study. Infect Drug Resist. 15:7077–7093. 2022.
View Article : Google Scholar
|
|
12
|
Experimental Diagnosis Group and
Hematology Society Chinese Medical Association, . Consensus of
Chinese experts on morphologic analysis of blood cells. Zhonghua
Xue Ye Xue Za Zhi. 34:558–560. 2013.(In Chinese).
|
|
13
|
Chinese Society of Immunology and Clinical
Flow Cytometry Group, . Expert consensus on minimal residual
disease detection of acute leukemia and plasma cell neoplasms by
multi-parameter flow cytometry. Zhonghua Xue Ye Xue Za Zhi.
38:1001–1011. 2017.(In Chinese).
|
|
14
|
Li J and Niu T: Clinical research progress
of hematological malignancies complicated with active tuberculosis.
Zhonghua Xue Ye Xue Za Zhi. 34:1076–1079. 2013.(In Chinese).
|
|
15
|
World Health Organization (WHO), . WHO
operational handbook on tuberculosis Module 2. Screening Systematic
screening for tuberculosis disease. WHO; Geneva: 2021
|
|
16
|
Sheikhpour M, Mirbahari SN, Sadr M, Maleki
M, Arabi M and Abolfathi H: A comprehensive study on the
correlation of treatment, diagnosis and epidemiology of
tuberculosis and lung cancer. Tanaffos. 22:7–18. 2023.
|
|
17
|
Sun W, Zhang L, Liang J, Li X, Yang Y, Sun
W and Hou J: Comparison of clinical and imaging features between
pulmonary tuberculosis complicated with lung cancer and simple
pulmonary tuberculosis: A systematic review and meta-analysis.
Epidemiol Infect. 150:e432022. View Article : Google Scholar
|
|
18
|
Mei ZX, Han JF, Yu HW, Zhang Y, Ji P, Xie
Y and Hsueh PR: Detection of serum Aspergillus-specific IgM and IgG
antibody levels for the diagnosis of chronic pulmonary
aspergillosis developed in patients with tuberculosis. Eur J Clin
Microbiol Infect Dis. 42:1081–1089. 2023. View Article : Google Scholar
|
|
19
|
Gosangi B, Hatabu H and Hammer MM: Imaging
features of pulmonary leukemic infiltration with comparison of
lymphoid and myeloid leukemias. Curr Probl Diagn Radiol.
50:164–167. 2021. View Article : Google Scholar
|
|
20
|
Yoshifuji K, Toya T, Yanagawa N, Sakai F,
Nagata A, Sekiya N, Ohashi K and Doki N: CT classification of acute
myeloid leukemia with pulmonary infiltration. Jpn J Radiol.
39:1049–1058. 2021. View Article : Google Scholar
|
|
21
|
Dickinson JM, Aber VR and Mitchison DA:
Bactericidal activity of streptomycin, isoniazid, rifampin,
ethambutol, and pyrazinamide alone and in combination against
Mycobacterium tuberculosis. Am Rev Respir Dis. 116:627–635. 1977.
View Article : Google Scholar
|
|
22
|
Zhang Y and Jin J: Application of Bcl-2
inhibitor venetoclax in acute myeloid leukemia. Zhonghua Xue Ye Xue
Za Zhi. 42:438–440. 2021.(In Chinese).
|
|
23
|
DiNardo CD, Jonas BA, Pullarkat V, Thirman
MJ, Garcia JS, Wei AH, Konopleva M, Döhner H, Letai A, Fenaux P, et
al: Azacitidine and Venetoclax in Previously Untreated Acute
Myeloid Leukemia. N Engl J Med. 383:617–629. 2020. View Article : Google Scholar
|
|
24
|
Lee JB, Khan DH, Hurren R, Xu M, Na Y,
Kang H, Mirali S, Wang X, Gronda M, Jitkova Y, et al: Venetoclax
enhances T cell-mediated antileukemic activity by increasing ROS
production. Blood. 138:234–245. 2021. View Article : Google Scholar
|
|
25
|
Bouligny IM, Murray G, Doyel M, Patel T,
Boron J, Tran V, Gor J, Hang Y, Alnimer Y, Zacholski K, et al:
Venetoclax with decitabine or azacitidine in the first-line
treatment of acute myeloid leukemia. EJHaem. 4:381–392. 2023.
View Article : Google Scholar
|
|
26
|
De Leeuw DC, Ossenkoppele GJ and Janssen
JJWM: Older patients with acute myeloid leukemia deserve
individualized treatment. Curr Oncol Rep. 24:1387–1400. 2022.
View Article : Google Scholar
|
|
27
|
Yuan F, Li D, Li G, Cheng C and Wei X:
Synergistic efficacy of homoharringtonine and venetoclax on acute
myeloid leukemia cells and the underlying mechanisms. Ann Transl
Med. 10:4902022. View Article : Google Scholar
|
|
28
|
Li C, Dong L, Su R, Bi Y, Qing Y, Deng X,
Zhou Y, Hu C, Yu M, Huang H, et al: Homoharringtonine exhibits
potent anti-tumor effect and modulates DNA epigenome in acute
myeloid leukemia by targeting SP1/TET1/5hmC. Haematologica.
105:148–160. 2020. View Article : Google Scholar
|
|
29
|
Zhou Z, Zhao X, Suo X, Bai G, Shi Z, Luo
Y, Tan Y, Lu X, Yuan L, Zhang C, et al: Venetoclax combined with
homoharringtonine, cytarabine, and aclacinomycin (HAAV) as
induction therapy in newly diagnosed young adult acute myeloid
leukemia. Blood. 142 (Supplement 1):S15172023. View Article : Google Scholar
|
|
30
|
Liu K, Suo X, Bai G, Yan Z, Li Y, Zhang B,
He J, Li J, Wei S, Li Q, et al: Venetoclax combined with
homoharringtonine and cytarabine (HAV) as induction treatment in
elder or intensive chemotherapy (IC) ineligible patients with newly
diagnosed acute myeloid leukemia. Blood. 142 (Supplement
1):S42722023. View Article : Google Scholar
|
|
31
|
Li K, Zhao W, Liu Y, Gao X, Zhou F, Chen
Q, Chang Y and Wang W: The value of venetoclax blood concentration
monitoring in the treatment of acute myeloid leukemia and the
efficacy and safety of combined azacytidine in the treatment of
acute myeloid leukemia. J Clin Hematol. 35:812–816. 2022.(In
Chinese).
|
|
32
|
Jin H, Zhang Y, Yu S, Du X, Xu N, Shao R,
Lin D, Chen Y, Xiao J, Sun Z, et al: Venetoclax combined with
azacitidine and homoharringtonine in relapsed/refractory AML: A
multicenter, Phase 2 trial. J Hematol Oncol. 16:422023. View Article : Google Scholar
|
|
33
|
Mirgh S, Sharma A, Shaikh MRMA, Kadian K,
Agrawal N, Khushoo V, Mehta P, Ahmed R and Bhurani D:
Hypomethylating agents+venetoclax induction therapy in acute
myeloid leukemia unfit for intensive chemotherapy-novel avenues for
lesser venetoclax duration and patients with baseline infections
from a developing country. Am J Blood Res. 11:290–302. 2021.
|
|
34
|
Vachhani P, Flahavan EM, Xu T, Ma E,
Montez M, Gershon A, Onishi M, Jin H, Ku G, Flores B, et al:
Venetoclax and hypomethylating agents as first-line treatment in
newly diagnosed patients with AML in a predominately community
setting in the US. Oncologist. 27:907–918. 2022. View Article : Google Scholar
|
|
35
|
Millanao AR, Mora AY, Villagra NA, Bucarey
SA and Hidalgo AA: Biological Effects of Quinolones: A family of
broad-spectrum antimicrobial agents. Molecules. 26:71532021.
View Article : Google Scholar
|
|
36
|
Ramon-Luing LA, Olvera Y, Flores-Gonzalez
J, Palacios Y, Carranza C, Aguilar-Duran Y, Vargas MA, Gutierrez N,
Medina-Quero K and Chavez-Galan L: Diverse cell death mechanisms
are simultaneously activated in macrophages infected by virulent
mycobacterium tuberculosis. Pathogens. 11:4922022. View Article : Google Scholar
|
